Immuneering Corporation (IMRX)
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.
$4.15-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+23.1%
The outlook
Immuneering Corporation currently reads as neutral based on strong buy — 1.3 avg of 7 analysts, below its 50- & 200-day averages, 17% of the way from its 52-week low to high, avg target +354% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 7 analysts
Price trendBelow its 50- & 200-day averages
52-week range17% of the way from its 52-week low to high
Price targetAvg target +354% vs current price
Analyst price target
~12-month · 7 analysts$18.86average target+354.4% vs now
Now $4.15
Low $12.00High $30.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$268.5M
52-wk high
$10.08
52-wk low
$2.90
50-day avg
$4.69
200-day avg
$5.44
Trailing P/E
—